Analgesic Efficacy of Different Doses of Esketamine as an Adjuvant to Ropivacaine for Thoracoscopy-Guided Thoracic Paravertebral Block After Thoracoscopic Radical Resection for Lung Cancer: A Prospective Randomized Controlled Trial.

Drug Des Devel TherSep 16, 2026 (epub)

Lu-Yao Wei, Ming-Can Luo, Jin-Xian He et al.

✦ AI-curated · Sources linked

Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.

From the abstract

Thoracoscopy-guided thoracic paravertebral block (TG-TPVB) is a new analgesia technique; however, the duration of a single TG-TPVB is short. Esketamine combined with local anesthetics can prolong the duration of nerve block.

Reported results

The time to first PCIA demand in the three esketamine groups were longer than in the control group. However, S2 and S3 groups were longer than S1 group. NRS pain scores in the three esketamine groups were lower than in the control group at 6, 12, 24, and 48 h postoperatively.

Authors' conclusions

Esketamine combined with ropivacaine for TG-TPVB prolonged postoperative analgesia, reduce pain scores, reduced analgesic consumption, and facilitated recovery. Esketamine at 0.2 mg/kg seems to show a good balance effect in many aspects.

Source

Published in Drug Des Devel Ther. The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Anesthesiology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.